Мадопар «250»

Quick links

Choose a section

Quick links to important sections

Advertisements

Мадопар «250»

Selected form

Advertisements
Advertisements
Advertisements

Overview of Мадопар «250»

Property Description
Active ingredient Levodopa and Benserazide
Form Oral formulation (Tablet or Capsule)
Pharmacological class Antiparkinsonian agent / Dopaminergic agent
General purpose Symptomatic support for impaired motor function
Origin Synthetic chemical compounds

Defining Мадопар «250»: Class and Identity

Мадопар «250» is a prescription-only medicine officially classified as an antiparkinsonian agent and a dopaminergic agent within the Anatomical Therapeutic Chemical (ATC) classification system. It is a strategically engineered fixed-dose combination product designed for oral administration, integrating two distinct synthetic chemical substances in a single unit. This dual-component approach is widely adopted in clinical practice.

The formulation combines the dopamine precursor Levodopa (L-DOPA) with the enzyme inhibitor Benserazide. This specific combination strategy is sold internationally under trade names such as Madopar and Prolopa, and the numerical portion, «250», indicates the total combined weight of the active ingredients in the specific tablet or capsule formulation.

Core Composition and Form

The medicine contains the active pharmaceutical ingredients Levodopa and Benserazide. While Levodopa functions as the essential precursor, its efficacy relies on the presence of Benserazide, which acts to protect it. The role of Benserazide is to selectively inhibit the enzyme that would otherwise break down Levodopa prematurely outside the brain, a process known as peripheral decarboxylation inhibition. This mechanism ensures that a greater quantity of the precursor successfully crosses the blood-brain barrier to reach its target. The product is manufactured as a solid oral formulation, which remains the standard method for administration.

General Purpose of the Combination

The general purpose of this specific drug combination is to provide symptomatic treatment by chemically counteracting a deficiency in the central nervous system. The combination facilitates targeted central dopamine replacement, which is essential for proper motor function. This therapeutic action is intended to mitigate physical manifestations such as rigidity and poor muscle control, thereby supporting enhanced functional movement. This chemical restoration is the intended general benefit of the dopaminergic agent.

Advertisements

What side effects are possible with Мадопар «250»?

Possible side effects and safety information

The official safety profile for the Levodopa and Benserazide combination is characterized by adverse reactions formally classified by frequency and affected physiological system. The most common effects reported in regulatory documents involve disturbances in the nervous, gastrointestinal, and cardiovascular systems.

Adverse Reaction Frequencies

Side effects are categorized based on the likelihood of their occurrence, as defined in official regulatory documents:

  • Very Common: These include dyskinesia (involuntary movements) and motor fluctuations.
  • Common: Reactions frequently documented are nausea, vomiting, diarrhea, anorexia, orthostatic hypotension, cardiac arrhythmias, insomnia, confusion, and hallucinations.
  • Rare: These less frequent events include changes to the blood and lymphatic system, such as hemolytic anemia, leukopenia, and thrombocytopenia.
  • Frequency Not Known: This category includes events like impulse control disorders (e.g., pathological gambling, hypersexuality), sudden onset of sleep, and symptoms resembling Neuroleptic Malignant Syndrome upon abrupt withdrawal.

Key Safety Patterns and Restrictions

Safety characteristics are often related to the duration of exposure. Gastrointestinal disturbances and orthostatic hypotension are commonly reported at the start of treatment or following dose increases. Conversely, motor fluctuations are typically associated with prolonged, long-term use of Levodopa-containing therapies.

Regulatory labeling outlines specific safety restrictions. Use is contraindicated in individuals with severe renal, hepatic, or endocrine disorders, or a history of malignant melanoma. The medication is also contraindicated when taken concurrently with non-selective monoamine oxidase inhibitors (MAOIs).

Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Мадопар «250»

Overdose Scope

Documented overdose presentations: Involuntary movements (dyskinesia), cardiac rhythm changes (sinus tachycardia), and acute central nervous system (CNS) disturbances, including mental confusion and agitation.

Physiological systems affected (as stated in label): Cardiovascular system (e.g., changes in heart rate and blood pressure) and Central Nervous System.

Dose-related or exposure-related factors (if applicable): The development of involuntary movements is documented as a clinical sign of toxicity, indicating overdosage that warrants professional assessment.

Population-specific overdose notes (if applicable): Adverse effects may occur particularly in elderly patients, which informs the clinical risk assessment in an overdose context.

Emergency-response statements (as written in official documents): Patients are required to contact a doctor or go to a hospital straight away and should take the medicine pack with them.

When immediate medical help is required (label-derived phrasing only): Immediate medical attention is required for all suspected cases of acute overdosage.


Overdose Classifications (High-Level)

Severity classification (as defined in official documents): Overdose may lead to severe cardiac disturbances, profound hypotension, and serious CNS effects, requiring in-hospital surveillance.

Regulatory basis (EMA / FDA / etc.): Prescribing Information and Summary of Product Characteristics (SmPC) for Levodopa/Benserazide.

Overdose-context constraints (as defined in official documents): Treatment is supportive and symptomatic; no specific antidote is known.


Resulting Overdose Structure

Official overdose statements:

  • Overdosage may present with involuntary movements and cardiac arrhythmias.
  • Immediate medical attention is required for all suspected cases.
  • Management of acute overdose is symptomatic and supportive, and involves continuous cardiac monitoring due to cardiovascular risk.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile primarily through manifestations of excessive dopaminergic stimulation, such as severe involuntary movements and dangerous cardiac rhythm changes. These documented clinical signs establish the explicit regulatory trigger for patients to seek immediate medical attention and ensures that they receive symptomatic and supportive treatment in a hospital setting. The official labeling confirms that no specific antidote is known, directing all emergency care toward stabilizing vital functions and managing the specific clinical findings.

Advertisements

Therapeutic Uses of Мадопар «250»

What Мадопар «250» Treats: Main Uses and Benefits

Мадопар «250» is a medication commonly used to provide symptomatic relief for motor function impairment in adults with Parkinson's disease. This combination medication is commonly used to help with symptom clusters that define Parkinsonian Syndromes, including bradykinesia, akinesia, muscular rigidity, and tremor at rest.

The therapeutic support contributes to easing the overall symptom load, which may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms. The therapy is relevant for providing supportive relief when symptoms create noticeable interference with daily stability and comfort. This is particularly relevant in clinical scenarios involving functional fluctuations or challenges like early morning stiffness and nocturnal immobility.

By addressing these pronounced symptoms, the medication may assist with the management of symptoms related to muscle control and provides supportive relief that helps patients cope more steadily with difficult episodes.


Therapeutic Focus: Management of Bradykinesia (Slowness of Movement)

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Мадопар «250» — Official Regulatory Information

Eligibility Scope

The medicine is officially allowed for use in Adults with Idiopathic Parkinson's disease. The elderly population is included, but requires careful titration.

Category Official Regulatory Statement
Populations for whom use is contraindicated Patients with known Hypersensitivity to levodopa/benserazide; those taking Non-Selective MAO Inhibitors; or those with a history of or suspected Malignant Melanoma.
Age-related eligibility rules Contraindicated in patients under 25 years of age to ensure skeletal development is complete.
Condition-specific eligibility rules Contraindicated in patients with Closed-Angle Glaucoma; Severe Cardiac Disorders; Severe Mental Problems with a psychotic component; or Decompensated Endocrine, Renal, or Hepatic Function.
Pregnancy and lactation eligibility status Contraindicated in pregnant women and women of childbearing potential not using adequate contraception; Breastfeeding is not recommended.

Eligibility Classifications (High-Level)

Category Official Regulatory Classification
Eligibility severity classification Contraindicated is the primary classification for patients with severe organ, cardiac, or psychiatric decompensation, and for the pediatric/pregnancy populations.
Eligibility-context constraints Use requires regular intraocular pressure monitoring in patients with Wide-Angle Glaucoma. No dose reduction is required for Mild or Moderate Renal Insufficiency, but caution is advised.

Resulting eligibility structure

The official regulatory documents strictly define who can and cannot use the medicine by establishing clear prohibitions for specific age groups, reproductive states, and severe systemic conditions, ensuring only approved populations receive treatment.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Мадопар «250» is established by strict constraints documented in government regulatory sources, which define both prohibited combinations and specific administration requirements.

Contraindicated Combinations and Procedural Restrictions

Co-administration with Non-selective Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated due to the documented risk of hypertensive crisis, a prohibition that also extends to the combined use of selective MAO-A and MAO-B inhibitors. Sympathomimetic Agents are likewise prohibited because official documentation notes a potentiation of cardiovascular effects. A procedural restriction requires the medicine to be formally discontinued 12 to 48 hours prior to general anesthesia involving Halothane due to concerns about cardiovascular stability.

Pharmacokinetic and Pharmacodynamic Effects

The regulatory profile identifies specific pharmacokinetic interactions: COMT Inhibitors officially increase the plasma exposure ( AUC) of Levodopa, and Iron Salts officially reduce Levodopa's intestinal absorption. This reduction in absorption is also documented for protein-rich meals, requiring specific timing separation to maintain adequate plasma concentrations. Furthermore, Antipsychotic Agents (Neuroleptics) are officially documented to cause pharmacodynamic antagonism, which may counteract the medicine's central effect. Co-administration with antihypertensive medicines carries a documented risk of orthostatic hypotension, a caution that is specifically highlighted in regulatory labels for elderly patients.

These restrictions and separation requirements are central to the drug's official regulatory interaction profile, ensuring administration aligns with documented pharmacokinetic and pharmacodynamic boundaries.

Advertisements

Mechanism of Action

️ Maximizing Central Precursor Availability

This mechanism is a dual-component strategy: Benserazide acts as a peripheral inhibitor of the AADC enzyme to prevent the premature breakdown of Levodopa outside the central nervous system (CNS). This protection increases the fraction of Levodopa that successfully crosses the blood-brain barrier via the LAT1 transporter to reach its active site.


Restoring Dopaminergic Neurotransmission

Once in the CNS, the protected Levodopa is converted into the active neurotransmitter Dopamine by residual AADC within surviving neurons. The resulting Dopamine acts as an agonist on postsynaptic Dopamine Receptors, establishing signaling in the nigrostriatal pathway .


️ Re-establishing Motor Circuit Balance

The restored central dopaminergic signal establishes an inhibitory influence on the basal ganglia motor loop. This physiological adjustment modulates the dynamics of neural activity patterns governing motor output, affecting muscle tone regulation and movement initiation.


️ Functional Constraints of the Mechanism

The drug's mechanism is functionally constrained by the presence and activity level of residual AADC-containing neurons required to perform the final conversion step. Additionally, the transport of Levodopa into the brain is subject to competitive inhibition at the LAT1 transporter, functionally limiting central availability.

Advertisements

Dosage and Administration Information

The administration of Мадопар is strictly oral, utilizing various dosage forms including hard capsules, standard tablets, and dispersible tablets. Treatment is established through a process of gradual, step-wise titration.

Therapy typically begins with a lower strength formulation, such as 50 mg Levodopa / 12.5 mg Benserazide, taken in divided doses three or four times daily. The dose is subsequently increased at intervals of one to two weeks until the individual's optimal response is achieved.

The Мадопар «250» strength, containing 200 mg of Levodopa and 50 mg of Benserazide, is designated primarily for maintenance therapy once the dose has been stabilized. The usual effective daily maintenance range is between 300 mg and 800 mg of Levodopa, which is divided across multiple administrations throughout the day.

Standard administration involves taking formulations either at least 30 minutes before or 1 hour after meals to minimize interference from dietary protein on absorption. Capsules must be swallowed whole, and dispersible tablets must be mixed in a small amount of water and consumed promptly.

Regarding specific patient populations, the dosage requires careful titration when used in older adults. The medication is not authorized for patients under 25 years of age due to concerns about completed skeletal development. In the event of a missed dose, the standard procedure is to skip the missed dose entirely and take the next scheduled dose; a double dose must never be taken.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trial Overview

Research has explored whether levodopa/benserazide influences symptom scores in adults with Parkinson’s syndrome, excluding medicine-induced parkinsonism. Major phase III studies involved randomized, double-blind, placebo-controlled trials. The study design examined the drug’s association with a reduction in core symptoms compared to placebo over various periods, typically 12 weeks, with secondary endpoints focusing on overall well-being scores.

Efficacy and Symptom Management

  • Primary Symptom Change: Studies have examined whether there was a change in reported motor symptoms and function, often measured by scales like the Unified Parkinson's Disease Rating Scale (UPDRS). Findings generally indicate that levodopa remains a highly effective option for alleviating motor signs of the condition, though individual responses can vary.
  • Quality of Life: Outcomes observed in the drug group have been associated with improvements in several quality-of-life domains, such as daily activity levels, compared to placebo in controlled studies. These differences require careful evaluation in the context of disease progression.
  • Formulation Studies: Research has explored different formulations. For instance, studies comparing dispersible levodopa/benserazide tablets with regular tablets have focused on their effect on time-to-ON (the time taken for medication effect to begin), particularly in patients experiencing delayed response to the first morning dose.

Patient Suitability and Safety Profiles

The trials primarily included adult participants with Parkinson’s syndrome. Participants with severe co-morbidities, such as severe renal or hepatic impairment, and certain conditions like narrow-angle glaucoma, were typically excluded from the initial studies. Research exploring drug-drug interactions has examined co-administration with common medications, though patients are always advised to consult a healthcare professional regarding all current prescriptions.

Ongoing Research

Ongoing clinical research continues to evaluate the long-term outcomes and safety profile of levodopa/benserazide treatment, particularly focusing on the management and potential postponement of motor fluctuations and dyskinesia that can develop with long-term therapy.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Мадопар «250» (FAQ)


Q: Почему именно «250»? Что означает эта цифра в названии?

The number «250» in the name indicates the total combined amount of the active ingredients in that specific dosage unit. According to official composition documents, this strength contains 200 mg of Levodopa and 50 mg of Benserazide.


Q: Это лекарство помогает только при дрожании или при других симптомах тоже?

Official documentation indicates the drug combination is used for symptomatic support in Parkinson’s syndrome. Its therapeutic effect is associated with alleviating a range of motor signs. These typically include rigidity, tremor, and poor muscle control.


Q: Когда начинает действовать Мадопар «250» после начала приема?

Studies have examined the 'time-to-ON,' which is the time taken for the medication's effect to begin. Official instructions state that the standard formulation is to be taken on an empty stomach to optimize how quickly the active ingredients are absorbed.


Q: Сколько по времени можно принимать Мадопар «250»?

Treatment for Parkinson’s disease is generally considered to be a long-term therapy. Clinical research continues to evaluate the long-term outcomes and safety profiles of continuous treatment with this medication.


Q: Может ли Мадопар «250» влиять на сон? Вызывает ли он бессонницу?

The official safety profile lists insomnia (difficulty sleeping) as a common side effect. Less frequently documented effects include sudden onset of sleep and excessive daytime sleepiness (somnolence).


Q: Есть ли побочные эффекты, которые требуют немедленного обращения к врачу?

Regulatory documents describe the need for immediate medical attention for signs of rare but serious adverse reactions. These can include symptoms of a severe nervous system reaction (like Neuroleptic Malignant Syndrome) or signs of gastrointestinal bleeding.


Q: Правда ли, что Мадопар может вызывать галлюцинации?

Hallucinations are listed as a common adverse reaction in the official safety profile for the Levodopa and Benserazide combination.


Q: Что делать, если при приеме Мадопар «250» появилась тошнота?

To help address this common side effect, official instructions mention the possibility of taking the medicine with a small, low-protein snack. If symptoms continue, reporting them to a healthcare professional is described as appropriate.


Q: Правда ли, что Мадопар может вызывать привыкание или зависимость?

The official safety profile mentions that patients treated with dopaminergic agents may develop Impulse Control Disorders (ICDs). Symptoms resembling Dopamine Dysregulation Syndrome, which includes cravings for larger doses, have also been documented in the 'Frequency Not Known' category.


Q: Правда ли, что Мадопар может вызывать неконтролируемые движения (дискинезию)?

Dyskinesia (uncontrolled, involuntary movements) is listed as a very common adverse reaction in the safety documents. This side effect is typically associated with the prolonged, long-term use of Levodopa-containing therapies.


Q: Нужно ли принимать Мадопар «250» в строго одно и то же время каждый день?

Official instructions specify that the medicine should be taken in divided doses throughout the day and at precise intervals relative to meals. Consistency in dosing times is described in official information as being important for the continuous management of symptoms.


Q: Можно ли пропустить прием таблетки Мадопар «250» и что тогда будет?

Official guidance is to skip the missed dose entirely and take only the next scheduled dose; a double dose must never be taken. Missing a dose may result in a temporary worsening of Parkinson's disease symptoms until the next administration.


Q: Разрешен ли прием Мадопар «250» при вождении автомобиля?

Official labeling contains a strict warning that individuals who experience somnolence (excessive sleepiness) or sudden sleep onset are not permitted to drive or operate machinery. This prohibition is due to the potential safety risk of sudden sleep attacks.


Q: Можно ли употреблять алкоголь во время лечения Мадопар «250»?

Regulatory warnings advise caution with alcohol consumption. Alcohol may intensify the central nervous system side effects of Levodopa, which can include dizziness, drowsiness, and impaired concentration.


Q: Какое взаимодействие у Мадопар «250» с витаминами и добавками?

The regulatory interaction profile primarily specifies the interaction with Iron salts, noting that they can reduce Levodopa's absorption. Other common vitamin or supplement interactions are not extensively restricted in the official documentation.


Q: Можно ли принимать Мадопар «250» вместе с другими лекарствами от Паркинсона?

Combination with other anti-Parkinsonian drugs is generally permissible as an approved practice. Official information notes that both desired and undesired effects may be intensified when used together.


Q: Если у меня депрессия, можно ли принимать Мадопар «250»?

Regulatory documents state the medicine is contraindicated (should not be used) in patients with severe mental problems that involve a psychotic component. Depression itself is listed as a potential side effect, or a condition that requires caution.


Q: Какие анализы или обследования нужно проходить во время приема Мадопар «250»?

Official documentation requires regular monitoring for certain conditions during the course of treatment. This includes monitoring for the development of melanoma and the emergence of impulse control disorders.


Q: Как узнать, что лекарство перестало работать или работает не так, как раньше?

The development of motor fluctuations is a common adverse reaction associated with long-term therapy. This involves an unpredictable switching between being able to move freely ('ON' periods) and experiencing immobility ('OFF' periods).


Q: Влияет ли Мадопар «250» на способность концентрироваться или память?

The official safety profile lists confusion as a common side effect. Since confusion can involve disturbances in thinking and attention, this indicates a potential influence on mental state and concentration.


Q: Какая связь между Мадопар «250» и контролем импульсивного поведения?

Regulatory safety documents state that patients treated with dopaminergic agents may develop Impulse Control Disorders (ICDs). This is a set of behavioral conditions that can include pathological gambling, hypersexuality, or compulsive buying.


Q: Почему важно не превышать рекомендованные дозы Мадопар «250»?

Official documentation describes the symptoms of an overdose of Levodopa and Benserazide. These effects can include changes in heart rhythm, increased confusion, difficulty sleeping, and experiencing unusual uncontrolled movements (dyskinesia).


Q: Можно ли принимать Мадопар «250» при язве желудка?

Regulatory warnings describe that Levodopa use is associated with a risk of worsening gastric or duodenal ulcers. Official guidance states that symptoms such as vomiting blood require the drug to be stopped and immediate medical attention to be sought.


Q: Как правильно хранить упаковку Мадопар «250»?

Official storage requirements instruct that the medicine should be protected from moisture and kept below 25 C or 30 C (depending on the region/formulation). It must be kept in its original, tightly closed container, and out of the sight and reach of children.


Q: Почему в инструкции говорится о возможном влиянии на анализ мочи?

The medicine can cause a noticeable change in the color of body fluids. Official safety information describes that urine may appear slightly red or dark, which is a normal color change due to the drug and is not typically a cause for concern.

Advertisements

How should Мадопар «250» be stored and disposed of?

Official Storage and Disposal Requirements

To ensure product stability, Madopar (Levodopa/Benserazide) must be stored under defined conditions, as instructed in regulatory labeling:

  • Temperature and Protection: The medicine must be kept at or below 25 C (or below 30 C depending on the formulation/region) and protected from moisture.
  • Packaging Rules: Store the medicine in its original container and keep the bottle tightly closed.
  • Child Safety: It is mandatory to keep Madopar out of the sight and reach of children.
  • Expiry: Do not use the medicine after the expiry date (EXP) printed on the packaging.
  • Disposal: Do not throw away unused or expired medicine in household waste or wastewater. Consult your pharmacist for instructions on proper pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Мадопар «250» found in:

A-Z Index: